Page 16 - Demo
P. 16
Chapter 114of FOLFIRINOX is frequently considered when disease progression occurs after a therapy free period of 4-6 months since the last FOLFIRINOX administration. Data supportive of the efficacy of this approach are however limited. In chapter 3, we investigated the reintroduction of FOLFIRINOX in patients who had previously benefited from first-line FOLFIRINOX treatment for both metastatic and nonmetastatic PDAC. This real-world cohort study utilized data from the NCR with the aim to find the most suitable patient category for this reintroduction approach.
